Results 11 to 20 of about 3,108,169 (356)
JAAD Case Reports, 2015 In the United States, the incidence of melanoma is increasing faster than any other preventable cancer. Acral melanoma is the fourth most common type of cutaneous melanoma and is frequently diagnosed later in its course compared with melanoma in other anatomic locations. Here we describe a case of highly advanced acral melanoma.
Lambert Smith, Franki +2 more
openaire +2 more sources
Immunotherapy for Advanced Melanoma [PDF]
Journal of Investigative Dermatology, 2008 Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed.
Fang, Lei +2 more
openaire +2 more sources
Recent advancements in melanoma management [PDF]
Internal Medicine Journal, 2021 AbstractThe treatment options for patients with melanoma have expanded significantly over the past decade. In particular, the use of targeted therapy and immunotherapy has dramatically transformed the outlook for patients with advanced disease. These treatments are now being utilised as adjuvant therapy for patients with earlier stage melanoma after ...
Tharani Krishnan +2 more
openaire +2 more sources
Dabrafenib plus trametinib versus nivolumab for advanced melanoma
Medwave, 2023 Introduction The incidence of cutaneous melanoma has increased worldwide over the years, and an incidence of 3 cases per 100,000 men and women is estimated in Chile.
Daniela Lahoz +2 more
doaj +1 more source
OUR EXPERIENCE WITH DACARBAZINE IN THE TREATMENT OF PATIENTS WITH INOPERABLE SKIN MELANOMA [PDF]
Journal of IMAB, 2016 Objective: The standard treatment for inoperable skin melanoma is chemotherapy. The aim of this study was to explore the efficacy and safety of therapy with dacarbazine in patients with advanced melanoma.
Deyan Davidov
doaj +1 more source
Journal of Clinical Oncology, 2023 PURPOSE Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti–programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation.
P. Ascierto +21 more
semanticscholar +1 more source
Translational Oncology, 2020 Real-world data on BRAF mutation frequency in advanced melanoma are lacking in Spain. Moreover, data available on clinicopathological profile of patients with advanced BRAF-mutant melanoma are currently limited.
Jose A. Lopez-Martin +11 more
doaj +1 more source
Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
JACC: Case Reports, 2019 Malignant melanoma demonstrates the highest rate of cardiac metastases. The incidence of melanoma is rising. The prognosis of people with advanced melanoma is generally poor.
Frederik Uttenthal Larsen, MD +2 more
doaj +1 more source
Frontiers in Oncology, 2023 The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the
Lucía Vázquez-Montero +4 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2022 Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed ...
J. Chesney +25 more
semanticscholar +1 more source